SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Robert G. Harrell who wrote (1481)1/14/2000 12:19:00 PM
From: debrahaugen  Respond to of 1754
 
Murphy appears to overstate his track record. According to Forbes Magazine's January 24, 2000 issue, Murphy's track record since 5/31/90 is an annual gain of 7.5% per annum. Murphy is rated a "B" in up markets and a "D" in down markets.
The article rates the Chartist as the best risk adjusted performance newsletter since 5/31/90.



To: Robert G. Harrell who wrote (1481)1/14/2000 2:12:00 PM
From: MGV  Respond to of 1754
 
Yes, it is wrong. ViSX has an action against Nidek for patent infringement in the ND of Calif federal district court. Nidek did counterclaim I believe with an antitrust-based claim against VISX.

I agree with you that there is a slew of misconstrued and misinterpreted facts and flawed conclusions therefrom regarding this industry.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News